Document is current
Any future updates will be listed below
-
Authors
Lin, Andrew L.
Rudneva, Vasilisa A.
Richards, Allison L.
Zhang, Yanming
Woo, Hyung Jun
Cohen, Marc
Tisnado, Jamie
Majd, Nazanin
Wardlaw, Sharon L.
Page-Wilson, Gabrielle
Sengupta, Soma
Chow, Frances
Goichot, Bernard
Ozer, Byram H.
Dietrich, Jorg
Nachtigall, Lisa
Desai, Arati
Alano, Tina
Ogilive, Shahiba
Solit, David B.
Bale, Tejus A.
Rosenblum, Marc
Donoghue, Mark T. A.
Geer, Eliza B.
Tabar, Viviane
-
Funding
Funding for this research was provided by:
National Institutes of Health (R21 CA280469-01)
National Institutes of Health (P30 CA008748)
Cycle for Survival
Marie-Josée and Henry R. Kravis Center for Molecular Oncology
- License Information
-
More Information
Article History
Received: 21 February 2024
Revised: 21 April 2024
Accepted: 22 April 2024
First Online: 17 May 2024
Declarations
:
: Andrew L. Lin reports research funding from Bristol Myers Squibb. Lisa Nachtigall and Eliza B. Geer report research funding from Recordati. David B. Solit has consulted/received honoraria from Rain Pharmaceuticals, Pfizer, Fog Pharma, PaigeAI, BridgeBio, Scorpion Therapeutics, FORE Therapeutics, Function Oncology, Pyramid, and Elsie Biotechnologies, Inc. The remaining authors have no disclosures to report.
: Patients with PitNETs were enrolled on a sequencing protocol (NCT01775072) that was approved by the MSKCC Institutional Review Board and conducted in accordance with International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws, after providing written informed consent.
